NO and PGI2 in coronary endothelial dysfunction in transgenic mice with dilated cardiomyopathy

[1]  V. Kozlovski,et al.  Prostacyclin, but not nitric oxide, is the major mediator of acetylcholine-induced vasodilatation in the isolated mouse heart. , 2007, Pharmacological reports : PR.

[2]  I. Rozenberg,et al.  Inactivity of nitric oxide synthase gene in the atherosclerotic human carotid artery , 2007, Basic Research in Cardiology.

[3]  M. Carrier,et al.  Alterations in the endothelial G-protein coupled receptor pathway in epicardial arteries and subendocardial arterioles in compensated left ventricular hypertrophy , 2007, Basic Research in Cardiology.

[4]  D. Waters,et al.  Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. , 2006, Journal of cardiac failure.

[5]  S. Nakatani,et al.  Impaired Systolic torsion in dilated cardiomyopathy: Reversal of apical rotation at mid-systole characterized with magnetic resonance tagging method , 2006, Basic Research in Cardiology.

[6]  T. Lüscher,et al.  Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. , 2006, Cardiovascular drug reviews.

[7]  P. Pagliaro,et al.  Post–conditioning reduces infarct size in the isolated rat heart: Role of coronary flow and pressure and the nitric oxide/cGMP pathway , 2006, Basic Research in Cardiology.

[8]  Raymond J Kim,et al.  Technology Insight: MRI of the myocardium , 2005, Nature Clinical Practice Cardiovascular Medicine.

[9]  V. Kozlovski,et al.  Compensation of Endothelium-Dependent Responses in Coronary Circulation of eNOS-Deficient Mice , 2005, Journal of cardiovascular pharmacology.

[10]  V. Ullrich,et al.  Peroxynitrite provides the peroxide tone for PGHS‐2‐dependent prostacyclin synthesis in vascular smooth muscle cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Stuart D Katz,et al.  Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure , 2005, Circulation.

[12]  T. LeJemtel,et al.  Endothelial Cell Activation in Patients With Decompensated Heart Failure , 2005, Circulation.

[13]  R Busse,et al.  gp91phox-Containing NADPH Oxidase Mediates Endothelial Dysfunction in Renovascular Hypertension , 2004, Circulation.

[14]  C. Stefanadis,et al.  Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. , 2004, International journal of cardiology.

[15]  J. Bauersachs,et al.  Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. , 2004, Current vascular pharmacology.

[16]  D. Mann,et al.  Cyclooxygenase-2 Inhibitor Treatment Improves Left Ventricular Function and Mortality in a Murine Model of Doxorubicin-Induced Heart Failure , 2004, Circulation.

[17]  A. Shah,et al.  Increased myocardial NADPH oxidase activity in human heart failure. , 2003, Journal of the American College of Cardiology.

[18]  A. Shah,et al.  Oxidative stress and heart failure. , 2003, Coronary artery disease.

[19]  A. Shah,et al.  Activation of NADPH Oxidase During Progression of Cardiac Hypertrophy to Failure , 2002, Hypertension.

[20]  P. Buttrick,et al.  Oxygen free radicals and heart failure: new insight into an old question. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[21]  M. Lewis,et al.  Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. , 2001, American journal of physiology. Heart and circulatory physiology.

[22]  A. Cunningham,et al.  Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. , 2001, The Journal of clinical investigation.

[23]  E. Neer,et al.  Dilated cardiomyopathy in two transgenic mouse lines expressing activated G protein alpha(q): lack of correlation between phospholipase C activation and the phenotype. , 2001, Journal of molecular and cellular cardiology.

[24]  J. Headrick,et al.  Functional characterization of coronary vascular adenosine receptors in the mouse , 2001, British journal of pharmacology.

[25]  A. Kamkin,et al.  Inotropic response to β‐adrenergic receptor stimulation and anti‐adrenergic effect of ACh in endothelial NO synthase‐deficient mouse hearts , 2001, The Journal of physiology.

[26]  Martin J. Lohse,et al.  Dobutamine-Stress Magnetic Resonance Microimaging in Mice: Acute Changes of Cardiac Geometry and Function in Normal and Failing Murine Hearts , 2001, Circulation research.

[27]  G. FitzGerald,et al.  Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. , 2000, Blood.

[28]  T. Saito,et al.  Cyclooxygenase-2 and nuclear factor-kappaB in myocardium of end stage human heart failure. , 1999, Congestive heart failure.

[29]  D. Harrison,et al.  Increased superoxide in heart failure: a biochemical baroreflex gone awry. , 1999, Circulation.

[30]  E. Neer,et al.  Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Wu,et al.  Cyclooxygenase-2 induction in congestive heart failure: friend or foe? , 1998, Circulation.

[32]  I. Rodger,et al.  Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. , 1998, Circulation.

[33]  T. Giles,et al.  Human and rat neutrophils constitutively express neural nitric oxide synthase mRNA. , 1998, Nitric oxide : biology and chemistry.

[34]  W. Seeger,et al.  Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. , 1998, American journal of respiratory cell and molecular biology.

[35]  H. Bidmon,et al.  Coronary hemodynamics in endothelial NO synthase knockout mice. , 1998, Circulation research.

[36]  J. Zweier,et al.  Validation of Lucigenin (Bis-N-methylacridinium) as a Chemilumigenic Probe for Detecting Superoxide Anion Radical Production by Enzymatic and Cellular Systems* , 1998, The Journal of Biological Chemistry.

[37]  G. Fishman,et al.  Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. , 1997, The Journal of clinical investigation.

[38]  Hisahiro Yu,et al.  Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression. , 1997, Hypertension.

[39]  G. Dorn,et al.  Transgenic Gαq overexpression induces cardiac contractile failure in mice , 1997 .

[40]  Lee-Ho Wang,et al.  Comparison of Hydroperoxide Initiator Requirements for the Cyclooxygenase Activities of Prostaglandin H Synthase-1 and −2 (*) , 1995, The Journal of Biological Chemistry.

[41]  A. Tsai,et al.  Spectroscopic Evidence for Reaction of Prostaglandin H Synthase-1 Tyrosyl Radical with Arachidonic Acid (*) , 1995, The Journal of Biological Chemistry.

[42]  M. Rudnicki,et al.  Simplified mammalian DNA isolation procedure. , 1991, Nucleic acids research.

[43]  A. K. Pedersen,et al.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.

[44]  A. Jasiński,et al.  MR Imaging of Mouse Heart in vivo Using a Specialized Probehead and Gradient System , 2006 .

[45]  U. Flögel,et al.  Direct comparison of magnetic resonance imaging and conductance microcatheter in the evaluation of left ventricular function in mice , 2005, Basic Research in Cardiology.

[46]  S. Neubauer,et al.  Serial high resolution 3D–MRI after aortic banding in mice: band internalization is a source of variability in the hypertrophic response , 2005, Basic Research in Cardiology.

[47]  F. Recchia,et al.  Acute and Chronic Endothelial Dysfunction: Implications for the Development of Heart Failure , 2004, Heart Failure Reviews.

[48]  M. Vallotton,et al.  Role of cyclooxygenase 2, p38 and p42/44 MAPK in the secretion of prostacyclin induced by epidermal growth factor, endothelin-1 and angiotensin II in rat ventricular cardiomyocytes. , 2003, Journal of molecular and cellular cardiology.

[49]  J. Schrader,et al.  Endothelial dysfunction of coronary resistance vessels in apoE-/- mice involves NO but not prostacyclin-dependent mechanisms. , 2002, Cardiovascular research.

[50]  T. Niitsuma,et al.  Alterations of endothelium-dependent and -independent regulation of coronary blood flow during heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.

[51]  K. Pritchard,et al.  Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. , 1996, Circulation research.

[52]  V. Ullrich,et al.  Low levels of hydrogen peroxide enhance platelet aggregation by cyclooxygenase activation. , 1991, Eicosanoids.